Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and maintained a $20 price target.
July 17, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on ORIC Pharmaceuticals and maintained a $20 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and the maintenance of a $20 price target by a reputable analyst suggests positive sentiment and confidence in ORIC Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100